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Various parotid gland diseases are seen clinically, in-
cluding inflammation, sialolithiasis, and benign and
malignant tumors. It is important to differentiate
among these to make a correct diagnosis and manage
them properly. Parotid gland disease often presents as
a subauricular mass, with or without pain. Fine-needle
aspiration cytology is used for preoperative diagnosis
of parotid gland disease in many institutes. However,
tumor seeding is the risk of this procedure, although
the occurrence rate is low [1]. Few studies have in-
vestigated the relationship between the characteristics
and type of parotid gland disease. In this study, we
retrospectively reviewed patients with parotid gland
disease that was managed by surgery in our institute
from 1998 to 2008. We discuss the relationship between
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Various parotid gland diseases are seen clinically, including inflammation, sialolithiasis, and
benign and malignant tumors. It is important to differentiate between these to make a correct
diagnosis and for proper management. Here, we investigated the relationship between tumor
characteristics and pathology, and considered whether the former could be used to differentiate
malignant from benign parotid gland diseases. We retrospectively reviewed the charts and data
of 316 patients who underwent surgery in Kaohsiung Medical University Chung-Ho Memorial
Hospital from January 1, 1998 to December 31, 2008. Two hundred and eighty-one patients
(88.9%) had benign disease, and 35 (11.1%) had malignant disease. The most common benign dis-
ease was pleomorphic adenoma (115 cases, 36.4%), but the most common disease in male
patients was Warthin’s tumor, a finding which, as far as we aware, has not been previously been
reported in the literature. The incidence of Warthin’s tumor seems to be increasing. In malignant
disease, the most common was acinic cell carcinoma (8 cases, 22.9%). Compared with benign dis-
ease, malignant parotid gland disease more often presents as a hard, painful, fixed and large
mass (> 3 cm), and more often involves the deep lobe of the parotid gland. Partial parotidectomy
was adequate for most tumors, including pleomorphic adenoma. The most common postopera-
tive complication was temporary facial palsy, followed by permanent facial palsy. However,
there was no difference in transient facial palsy rate between benign and malignant parotid 
gland disease, although parotid gland cancer had a higher incidence of permanent facial palsy
postoperatively.
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tumor characteristics and pathology, and consider
whether the former can be used to differentiate malig-
nant from benign parotid gland tumors. The results of
surgery and its complications are also discussed.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of
patients with parotid gland disease who received sur-
gical treatment at the Department of Otolaryngology
of Kaohsiung Medical University Hospital from
January 1, 1998 to December 31, 2008. A total of 377
patients with parotid gland disease who were sched-
uled for surgery were identified through the comput-
erized database in our department. However, the
charts of 48 patients were not available. Of the remain-
ing 329 patients, 13 did not undergo surgery for per-
sonal reasons or poor physical status. The remaining
316 patients formed the study group and their medical
records were reviewed.
All of the surgery was performed by one of our
three senior head and neck surgeons. Neck computed
tomography (CT) was routinely performed before sur-
gery. All operations were carried out under general
anesthesia. The type of operation was dependent upon
the character of the tumor, and included partial super-
ficial, deep or total parotidectomy. The greater auricu-
lar nerve was sacrificed if necessary. Neck dissection
was performed if enlarged neck lymph nodes were
found by CT or physical examination. If malignant
parotid gland disease was highly suspected during
surgery, a specimen was sent for frozen section exam-
ination to determine if a more extensive operation
was necessary. We routinely identified the facial nerve
during operation, and carefully dissected the parotid
gland tumor along the course of the facial nerve
branch. The facial nerve was preserved as far as pos-
sible, unless severe adhesion of the nerve to the sus-
pected malignant tumor was found, because of concern
about tumor recurrence. Intraoperative facial nerve
monitoring was not routinely used but was performed
on selected patients. Specimens were routinely sent
for pathological examination.
Radiotherapy or chemotherapy was selectively ar-
ranged for patients with malignant disease, depending
upon the pathology type and stage of the disease.
The following parameters were collected and 
analyzed: patient age at diagnosis, sex, tumor size,
symptom duration, tumor texture, tumor position,
type of operation performed, pathology, postoperative
complications, and follow-up time.
We used SPSS version 12.0 (SPSS Inc., Chicago, IL,
USA) for statistical analysis. Student’s t test was used
for between-group comparisons of continuous vari-
ables; the paired t test was used to compare paired
samples; and the χ2 test for analysis of categorical data.
A p value <0.05 was considered statistically significant.
RESULTS
The medical records of 329 patients were available
and reviewed. Thirteen patients did not undergo sur-
gery for personal reasons or poor physical status, and
were excluded from this study. A total number of 316
cases were included in the study and their data were
collected and analyzed.
Patient characteristics are shown in Table 1. The
average age at diagnosis was 49.4 ± 16.0 years (range,
3–82 years). There were 190 men (60.1%) and 126
women (39.9%). The maximal tumor diameter was
3.11 ± 1.34 cm (range, 1–10 cm). Two hundred and
eighty-one patients (88.9%) had benign disease, and
35 (11.1%) had malignant disease.
Among the 281 patients with benign parotid gland
disease (Table 2), the most common was pleomorphic
adenoma (115 cases, 40.9%), followed by Warthin’s
tumor (70 cases, 24.9%), and then chronic sialoadenitis
(30 cases, 10.7%). Benign disease was more common
in male patients (n = 169; 60.1%) than female patients
(n = 112; 39.9%) (Table 1).
There were 115 patients with pleomorphic ade-
noma in this series (Table 3). It was more common in
female (n=67; 58.3%) than male (n=48; 41.7%) patients.
For the surgical method, most patients (104 patients,
90.4%) received partial superficial parotidectomy
(Table 4), and no patient suffered from tumor recur-
rence after surgery.
Seventy patients with Warthin’s tumor were treated
in our institute (Table 3). The average age at diagno-
sis was 60.6 ± 10.6 years (range, 35–81 years). It was
more common in male (n = 61; 87.1%) than female 
(n = 9; 12.9%) patients. Two patients (2.9%) suffered
from tumor recurrence after surgery, and underwent
reoperation.
There were 35 cases of malignant parotid gland le-
sions, and their characteristics and pathological results
are shown in Tables 1 and 5, respectively. There were
21 male (60.0%) and 14 female (40.0%) patients. Pre-
operative tumor pain was noted in 17 patients (48.6%).
Nineteen patients (54.3%) had preoperative tumor
fixation. For preoperative tumor texture, 17 tumors
(48.6%) were hard, 17 (48.6%) were elastic (or firm),
and only one (2.9%) were soft. The most common ma-
lignant parotid gland disease was acinic cell carcinoma
(8 cases, 22.9%) (Table 5), followed by mucoepider-
moid carcinoma (6 cases, 17.1%). Eight patients (22.9%)
received postoperative radiotherapy. Among the six
patients with tumor recurrence (17.1%), three had acinic
cell carcinoma, one had adenosquamous carcinoma,
another had undifferentiated carcinoma, and the final
one had lymphoma. The patients with tumor recur-
rence were managed by reoperation, adjuvant radio-
therapy or chemotherapy.
The surgical complications are listed in Table 6.
The most common was temporary facial palsy, which
occurred in 60 patients (20.0%). Eight patients suf-
fered from permanent facial palsy after surgery, and
two of these cases were due to intentional sacrifice of
the facial nerve because of severe adhesion of the
nerve to the surrounding malignant tissue. The other
complications included hematoma, sialocele and
wound infection.
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Table 1. Characteristics of all parotid gland diseases patients and comparison of benign and malignant parotid gland
disease*
All Benign Malignant p
Number of cases 316 (100) 281 (88.9) 35 (11.1)
Sex 0.987
Male 190 (60.1) 169 (60.1) 21 (60.0)
Female 126 (39.9) 112 (39.9) 14 (40.0)
Age at diagnosis (yr) 49.4 ± 16.0 (3–82) 49.1 ± 16.2 (3–82) 51.5 ± 15.0 (19–81) 0.426
Tumor size (cm) 0.052
< 3 217 198 19
≥ 3 98 83 16
Maximal diameter (cm) 3.11 ± 1.34 (1–10) 3.08 ± 1.33 (1–10) 3.37 ± 1.41 (1.5–6.5) 0.224
Tumor location
Right side 150 (47.5) 132 (47.0) 18 (51.4)
Left side 163 (51.6) 146 (52.0) 17(48.6)
Bilateral 3 (0.9) 3 (1.1) 0 (0)
Symptom duration (mo) 23.55 ± 39.10 (0–360) 24.2 ± 38.49 (0–360) 18.26 ± 43.90 (0–240) 0.425
Tumor pain 49 (15.5) 32 (11.4) 17 (48.6) 0.000†
Tumor fixation 59 (18.7) 40 (14.2) 19 (54.3) 0.000†
Tumor texture 0.008†‡
Soft 26 (8.2) 25 (8.9) 1 (2.9)
Elastic/firm 197 (62.4) 180 (64.1) 17 (48.6)
Hard 93 (29.4) 76 (27.0) 17 (48.6)
Admission duration (d) 5.66 ± 2.16 (2–24) 5.47 ± 1.94 (2–24) 7.23 ± 3.06 (2–16) 0.002†
Tumor location 0.003†§
Superficial lobe 292 (92.4) 264 (94.0) 28 (80.0)
Deep lobe 20 (6.3) 15 (5.3) 5 (14.3)
Superficial + deep lobe 4 (1.3) 2 (0.7) 2 (5.7)
Average follow-up 12.53 ± 22.19 (0–127) 10.64 ± 20.92 (0–127) 27.69 ± 26.29 (0–117) 0.001†
period (mo)
Recurrence 8 (2.5) 2 (0.7) 6 (17.1) 0.000†
Radiotherapy 9 (2.8) 0 (0) 9 (25.7)
*Data presented as n (%) or mean ± standard deviation (range); †p < 0.05; ‡hard versus non-hard tumor (including elastic/firm and
soft tumors); §superficial versus deep lobe (including tumors confined to (benign vs. malignant) deep parotid lobe only and those
involving both superficial and deep parotid lobes).
DISCUSSION
Salivary gland tumors account for 3–6% of all head
and neck tumors, and 70–85% of salivary gland neo-
plasms originate in the parotid gland [2,4]. Generally,
the most common benign parotid gland neoplasm is
pleomorphic adenoma, and the most common mali-
gnant one is mucoepidermoid carcinoma. Apart from
tumors, various kinds of parotid gland diseases are
seen clinically. Most inflammatory parotid gland dis-
eases can be treated by conservative management
and few need surgical intervention, although surgery
is always necessary for parotid gland tumors.
In our study, parotid gland disease was more
common in male patients (male:female=3:2), and this
is similar to the result in a previous study [5]. Parotid
gland disease was most prevalent in the middle-aged
group (average age at diagnosis = 49.4 years).
In benign disease, the most common form was
pleomorphic adenoma (115 cases, 36.9%), followed by
Warthin’s tumor (70 cases, 22.15%). However, the most
common benign parotid gland disease in male patients
was Warthin’s tumor (61 cases, 32.1%), and not pleo-
morphic adenoma (48 cases, 25.3%). As far as we are
aware, this has not been reported previously.
In our study, pleomorphic adenoma was the most
common benign parotid gland disease, and it ac-
counted for 40.9% of all cases, which is similar to other
studies [6,7]. Pleomorphic adenoma was more com-
mon in women (male:female = 1:1.5), and this matches
the result by Eveson et al (male:female = 1:1.4) [6].
Most of our patients were between 35 and 55 years
old. Pleomorphic adenoma can have small projec-
tions that invade surrounding normal parotid tissue,
and the recurrence rate is high if only enucleation of
the tumor is performed, because the tumor can arise
from these small projections. Later complete superfi-
cial parotidectomy is suggested in superficial parotid
gland tumor, but the complication rate is increased
because of more extensive surgery. Recently, partial
parotidectomy (also called limited parotidectomy),
which means removal of tumor mass together with
1–2 cm of surrounding normal parotid tissue, has
been advocated [8,9]. Partial parotidectomy for benign
parotid gland lesions can remove the lesion without
increasing the recurrence rate and produce fewer com-
plications compared with those managed by com-
plete superficial parotidectomy [8]. In our institute,
we manage patients with pleomorphic adenoma by
partial parotidectomy in most cases (Table 4). No
recurrence of pleomorphic adenoma is found during
follow-up. However, the weak point is that our aver-
age follow-up time is not long (12.87 ± 25.47 months;
range, 0–127 months), and there is a possibility that
recurrence might occur later. Nevertheless, during
the past 10 years, no patient has visited us again due
to tumor recurrence.
The second most common benign parotid gland
tumor in our series was Warthin’s tumor, and it ac-
counted for 24.9% and 22.2% of benign parotid gland
disease and all parotid gland disease, respectively
(Tables 2 and 3). Eveson et al [6] have shown that
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Table 2. Histological type of benign parotid gland 
disease
Pathology n (%)
Benign epithelial tumor
Pleomorphic adenoma 115 (40.9)
Warthin’s tumor 70 (24.9)
Basal cell adenoma 7 (2.5)
Oncocytoma 4 (1.4)
Monomorphic adenoma 2 (0.7)
Myoepithelioma 1 (0.4)
Non-epithelial tumor
Lipoma 11 (3.9)
Fibrolipoma 2 (0.7)
Cavernous hemangioma 1 (0.4)
Desmoid tumor 1 (0.4)
Schwannoma 1 (0.4)
Parapharyngeal chondroma 1 (0.4)
Angioleiomyoma 1 (0.4)
Cystadenoma 1 (0.4)
Neurilemmoma 1 (0.4)
Cyst
Epidermoid cyst 3 (1.1)
Salivary duct cyst 1 (0.4)
Hemorrhagic cyst 1 (0.4)
Inflammation and infection
Chronic sialoadenitis (inflammation) 30 (10.7)
Lymph node reactive hyperplasia 8 (2.8)
Caseating granuloma 3 (1.1)
Actinomycosis 2 (0.7)
Kimura’s disease 2 (0.7)
Necrotizing sialometaplasia 1(0.4)
Others
Lymphoepithelial lesion 7 (2.5)
Sialolithiasis (stone) 2 (0.7)
Mucocele 1 (0.4)
Ductal ectasia 1 (0.4)
Granulomatous ductal stenosis 1 (0.4)
Total 281 (100)
Warthin’s tumor accounted for 6.9% of all parotid
gland tumors. A study by Upton et al [9] has reported
that 12.7% of benign parotid lesions were Warthin’s
tumor. Our occurrence rate for Warthin’s tumor was
higher than that in the above two studies. However, a
series based on an Asian population has shown that
Warthin’s tumor constituted 25% of all parotid gland
tumors [10], and this is consistent with our study.
Another study based on a Chinese population has
shown that Warthin’s tumor was the most common
benign parotid gland lesion (37%), which was even
more common than pleomorphic adenoma [11]. It
seems that Warthin’s tumor is more prevalent in ethnic
Chinese populations, but the exact reason is unknown.
Genetic factors should be considered. Epstein–Barr
virus (EBV) infection is prevalent in Southeast Asia.
Some earlier studies have described that EBV is found
in Warthin’s tumor and is thought to be related to
tumor occurrence [12,13]. However, more recent stud-
ies have proved that EBV infection is not involved in
the etiology of Warthin’s tumor [14,15]. Another well-
documented etiological factor in Warthin’s tumor is
cigarette smoking [16,17]. Asians in general have 
40 times increased risk of developing Warthin’s tumor
if they smoke [10].
In our study, Warthin’s tumor was prevalent in
older patients (average age = 60.6 ± 10.6 years), and
most (68 cases; 97%) were > 45 years. As a result, if a
Features of parotid gland disease
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Table 3. Comparison between pleomorphic adenoma and Warthin’s tumor*
Pleomorphic adenoma Warthin’s tumor p
Number of cases 115 (36.4)‡ 70 (22.2)‡ 0.000†
Sex
Male 48 (41.7) 61 (87.1) 0.000†
Female 67 (58.3) 9 (12.9)
Age at diagnosis (yr) 43.5 ± 13.9 (16–76) 60.6 ± 10.6 (35–81) 0.000†
Age (yr) 0.000†
< 45 64 2
≥ 45 51 68
Average tumor size (cm) 0.053
< 3 89 45
≥ 3 26 25
Maximal diameter (cm) 2.87 ± 1.16 (1.0–7.5) 3.28 ± 1.26 (1.5–8.0) 0.025†
Tumor location 0.101
Right side 60 (52.2) 25 (35.7)
Left side 54 (47.0) 39 (55.7)
Bilateral 1 (0.9) 6 (8.6)
Symptom duration (mo) 33.38 ± 46.87 (0–360) 19.79 ± 32.81 (0–216) 0.032†
Tumor pain 1 (0.9) 7 (10) 0.003†
Tumor fixation 14 (12.2) 8 (11.4) 0.897
Tumor texture 0.363§
Soft 3 (2.6) 7 (10.0)
Elastic/firm 73 (63.5) 54 (77.1)
Hard 39 (33.9) 9 (12.9)
Admission duration (d) 5.23 ± 1.20 (2–9) 5.47 ± 1.30 (4–12) 0.195
Tumor location 0.166
Superficial lobe 106 (92.2) 68 (97.1)
Deep lobe 8 (7.0) 2 (2.9)
Superficial + deep lobe 1 (0.9) 0 (0)
Average follow-up period (mo) 12.87 ± 25.47 (0–127) 9.07 ± 18.42 (0–94) 0.279
Recurrence 0 (0) 2 (2.9)
*Data presented as n (%) or mean ± standard deviation (range); †p < 0.05; ‡% from comparison with the total number of parotid dis-
ease; §hard versus non-hard tumor (including elastic/firm and soft tumors); superficial versus deep lobe (including tumors confined
to deep parotid lobe only and those involving both superficial and deep parotid lobes).
patient with parotid gland tumor is younger than 
45 years old, we can reasonably assume that his tumor
is not Warthin’s tumor. The male to female ratio was
6.8:1, and the ratio was higher than that in other stud-
ies [10,17]. Another interesting finding was that the
most common benign tumor in male patients in our
study was Warthin’s tumor (32.1%) and not pleomor-
phic adenoma (25.3%). Six patients (8.6%) had bilateral
Warthin’s tumor, and the incidence was consistent with
that in other studies [10,17]. In addition, a tendency
towards an increased occurrence rate of Warthin’s tu-
mor was found in our study (Figure), although this
contradicts Chung et al [10] who observed no increas-
ing incidence of Warthin’s tumor. The exact reason
for increasing incidence of Warthin’s tumor is un-
known, but it could be related to the present longer
lifespan and that more surgery is performed on older
people.
There were some different characteristics for the
two most common benign parotid gland tumors
(Table 3). First, the Warthin’s tumor was prevalent in
the older patient group, and most of them were male
(87.1%). In contrast, pleomorphic adenoma was more
prevalent in the middle-aged group (average age=43.5
years), and was more common in female patients
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Table 6. Postoperative complications in benign and
malignant gland diseases*
Complication Benign Malignant Total p†
Temporary 54 (19.2) 6 (17.1) 60 (20.0) 0.786
facial palsy
Permanent 3 (1.1) 5 (14.3) 8 (2.5) 0.000‡
facial palsy 
Hematoma 5 (1.8) 0 (0) 5 (1.6)
Frey’s syndrome 4 (1.4) 1 (2.9) 5 (1.6)
Sialocele 1 (0.4) 0 (0) 1 (0.3)
Infection 4 (1.4) 0 (0) 4 (1.3)
*Data presented as n (%); †benign versus malignant gland 
diseases; ‡p < 0.05.
Table 4. The operation method in different groups of parotid gland disease
Total Benign Malignant Pleomorphic adenoma Warthin’s tumor
Partial superficial parotidectomy 274 257 17 104 68
Complete superficial parotidectomy 7 2 5 2 0
Partial deep parotidectomy 8 8 0 2 2
Total parotidectomy 19 9 10 7 0
Neck dissection 6 0 6 0 0
Excision, enucleation 4 3 1 0 0
Incision and drainage 5 5 0 0 0
Biopsy 3 1 2 0 0
Table 5. Histological type of malignant parotid gland
disease
Pathology n (%)
Acinic cell carcinoma 8 (22.9)
Mucoepidermoid carcinoma 6 (17.1)
Adenoid cystic carcinoma 3 (8.6)
Malignant lymphoepithelial lesion 3 (8.6)
Salivary duct carcinoma 3 (8.6)
Lymphoma 3 (8.6)
Carcinoma ex pleomorphic adenoma 2 (5.7)
Adenocarcinoma 2 (5.7)
Metastatic tumor 2 (5.7)
Myoepithelial carcinoma 1 (2.9)
Undifferentiated carcinoma 1 (2.9)
Adenosquamous carcinoma 1 (2.9)
Total 35 (100)
Figure. Number of cases of Warthin’s and pleomorphic adenoma.
Increasing incidence and number of cases of Warthin’s tumor
was found during the last decade. PA = pleomorphic adenoma;
WT = Warthin’s tumor.
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(male:female=2:3). Compared with pleomorphic ade-
noma, the size of Warthin’s tumor was larger, but the
symptom duration was significantly shorter than
that of pleomorphic adenoma (Table 3). This implies
that the growth rate of Warthin’s tumor was faster
than that of pleomorphic adenoma. More tumor pain
was also noted in Warthin’s tumor (10%) than pleo-
morphic adenoma (0.9%).
Another group of parotid gland diseases is inflam-
matory diseases, and most of these inflammatory dis-
eases can be managed initially with medical treatment
including analgesics, antibiotics and mouthwashes.
If patients do not respond to medical treatments, or a
tumor cannot be excluded, or sialography shows ap-
preciably altered duct anatomy or sialolithiasis, then
surgical intervention becomes necessary [18]. Thirty
patients with chronic sialoadenitis have received pa-
rotidectomy in the past 10 years in our institute. Some
of them have received surgery because of persistent
symptoms such as chronic pain or parotid gland
swelling, and others have been operated upon under
suspicion of malignancy. Nevertheless, sometimes it
might be difficult to distinguish chronic parotitis from
parotid gland cancer because both conditions often
present as a painful mass. However, tumor fixation
was found in only six patients (20.0%) with chronic
parotitis but in 17 patients (48.6%) with parotid gland
cancer. Also, about half of the parotid gland cancer
(48.6%) presented as a hard mass, and only 20% (6
cases) of chronic parotitis is hard. Thus tumor texture
and mobilization could be used as clues to distin-
guish chronic parotitis from parotid gland cancer
preoperatively.
Thirty-five patients with malignant parotid gland
diseases were operated upon in our study (Table 2),
and the malignancy rate was 11.1%, which is compati-
ble with the wide range of malignancy rates reported
in other studies [2,19]. Among these patients, the
most common malignancy was acinic cell carcinoma
(8 cases, 22.9%), followed by mucoepidermoid carci-
noma (6 cases, 17.1%). However, the most common
malignant parotid gland disease described in the lit-
erature is mucoepidermoid carcinoma [20,21], and
not acinic cell carcinoma. This difference could be
associated with our small number of patients. Most of
our malignant parotid gland disease was managed
by partial or total parotidectomy. We did not rou-
tinely perform neck dissection unless there was an
enlarged lymph node noted preoperatively by physical
examination or CT. The management for N0 neck
remains controversial. Regis De Brito Santos et al [22]
have suggested that patients with high-risk histologi-
cal types and advanced tumor stage could benefit
from elective neck treatment. Most authors have
advocated performing neck dissection on the basis of
the histology of the primary parotid carcinoma and
the tumor grade, because these characteristics most
influence the risk of occult metastases in primary
salivary carcinoma [23,24]. We preserve the integrity
of the facial nerve unless there is tumor adhesion to
the facial nerve.
A recent study has shown that radical procedures
did not increase 5-year survival rates, and the integrity
of the facial nerve should be preserved unless the
nerve is imbedded in, or adherent to, the parotid car-
cinoma [25]. Six of our patients with parotid gland
cancer suffered from tumor recurrence, and the recur-
rence rate was 17.1%, which is similar to that in other
studies [20,26]. Patients with cancer recurrence were
managed with adjuvant radiotherapy or salvage oper-
ation, depending on the disease severity and patient’s
tolerance.
There were some different characteristics between
benign and malignant parotid gland diseases in our
study (Table 1). The incidence of tumor fixation and
tumor pain was significantly higher in malignant dis-
ease. Besides, about half of the malignant tumors were
palpated as hard masses, but only 27% of benign
parotid gland diseases were hard (p<0.05). In contrast,
malignant tumors more frequently involved the deep
lobe of the parotid gland (p < 0.05). Thus if we en-
counter patients with a parotid gland tumor that pres-
ents as a hard, tender, fixed or large mass, we should
suspect malignancy.
The most common postoperative complication
was temporary facial palsy (20.0%), followed by per-
manent facial palsy (2.5%). The occurrence rate of
temporary facial palsy did not differ between benign
and malignant tumors, but the occurrence rate of per-
manent facial palsy was significantly higher in ma-
lignant tumors (14.3%) (Table 6). Zbaren et al [20]
reported that the facial function impairment rate
after surgery for malignant parotid gland disease
was 16%. Guntinas-Lichius et al [27] reported a series
of 610 patients with benign parotid gland lesions that
were managed by surgery, and the facial palsy rate
was about 18%. O’Brien et al [7] reported a series of
363 patients with 24% and 3% rates of temporary 
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and permanent facial palsy, respectively. Our result is
similar to the above studies. Facial expression is
important for social activity, and preservation of the
facial nerve function is important. We used intraop-
erative electromyography for facial nerve monitoring
in selective cases. Although Meier et al [28] reported
that the electromyography facial nerve monitoring is
not reliable in predicting postoperative facial nerve
injuries, others consider that this system is beneficial
[29,30]. Some factors increase the risk of facial nerve
palsy. Huang et al [25] reported that the risk factors
for postoperative facial palsy include increasing
tumor size, deep lobe tumor location, and tumor
invasion of the facial nerve.
In conclusion, the various parotid gland diseases
should be carefully differentiated. In our study, the
most common benign parotid gland disease was pleo-
morphic adenoma. However, the most common be-
nign tumor in male patients was Warthin’s tumor, a
finding which, as far as we aware, has not previously
been reported. In addition, the prevalence rate of
Warthin’s tumor seems to be higher in ethnic Chinese
populations, although the exact reason is unknown.
Compared with benign parotid gland disease, malig-
nant disease more often presented as a hard, painful,
fixed and large mass, and involved the deep parotid
gland. Partial parotidectomy is a reliable surgical
method for most parotid gland diseases, including
pleomorphic adenoma. For postoperative complica-
tions, the occurrence rate of transient facial palsy did
not differ among benign and malignant parotid le-
sions, but the permanent facial palsy rate was signifi-
cantly higher for parotid gland cancer.
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南台灣腮腺疾病的特徵與手術結果分析
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腮腺存在著各式各樣的疾病，包括發炎、結石及良性或惡性腫瘤等。能鑑別並正確地
診斷對治療是很重要的。本篇研究希望藉由對腮腺疾病臨床特徵的分析，探討是否可
藉此於術前區分出惡性腮腺腫瘤。我們以回溯性方式收集自 1998 年 1 月 1 日至 2008 
年 12 月 31 日於高雄醫學大學附設醫院接受腮腺手術的病人，一共收集 316 個有效個
案，對其資料作統計分析。在這 316 個接受腮腺手術的病人中，281位（88.9%）是
良性疾病，35 位（11.1%）是惡性疾病。最常見的良性疾病是 pleomorphic adenoma
（115位；36.4%），但是在男性病人中，最常見良性腫瘤的卻是 Warthin’s tumor，
這在以前的文獻中未曾報告過。另一方面，Warthin氏腫瘤的盛行率似乎有上升的趨
勢。惡性疾病中，最常見的是 acinic cell carcinoma（8位；22.9%）。和良性腫瘤比較
起來，惡性腫瘤比較常表現出硬的、疼痛、固著及較大（> 3 cm）的腫塊，且較常侵
犯 腮 腺 的 深 葉（deep lobe）。 在 手 術 方 式 上， 局 部 腮 腺 切 除 術（partial 
parrotidectomy）對大部分的腮腺疾病是有效的，包括 pleomorphic adenoma。最常見
的術後併發症是暫時性顏面神經麻痺，其次是永久性顏面神經麻痺。然而，暫時性顏
面神經麻痺的發生率在良性和惡性腫瘤之間沒有差異，但惡性腫瘤術後出現永久性顏
面神經麻痺的機會較高。
關鍵詞：顏面神經麻痺，腮腺腫瘤，局部腮腺切除手術，pleomorphic adenoma，Warthin氏腫瘤
（高雄醫誌 2010;26:483–92）
